Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence
Eyes Post-Xtandi Revenues
Executive Summary
Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry.